Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users Katherine A. Belendiuk, Kimberly A. Babson, Ryan Vandrey, Marcel O. Bonn-Miller Addictive Behaviors, 2015, 50, 178–181 doi : 10.1016/j.addbeh.2015.06.032 a b s t r a c t Introduction : Individuals report using cannabis for the promotion of sleep, and the effects of cannabis on sleep may vary by cannabis species. Little research has documented preferences for particular cannabis types or cannabinoid concentrations as a function of use for sleep disturbances. Methods : 163 adults purchasing medical cannabis for a physical or mental health condition at a cannabis dispensary were recruited. They provided self-report of (a)whether [...]
Lire la suiteCANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2 Expert Committee on Drug Dependence Thirty-ninth Meeting, Geneva, 6-10 November 2017 39th ECDD (2017) Agenda item 5.2 Cannabidiol (CBD) Contents Acknowledgements .................................................................................................................. 4 Summary ................................................................................................................................... 5 1. Substance identification ........................................................................................................ 6 A. International Nonproprietary Name (INN) .......................................................................... 6 B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6 C. Other Chemical Names .......................................................................................................... 6 D. Trade Names .......................................................................................................................... 6 E. Street Names .......................................................................................................................... 6 F. Physical Appearance .............................................................................................................. 6 G. WHO Review History ............................................................................................................. 6 2. Chemistry ............................................................................................................................... 6 A. Chemical Name ...................................................................................................................... 6 B. Chemical Structure ................................................................................................................. 7 C. Stereoisomers ......................................................................................................................... 7 D. Methods and Ease of Illicit Manufacturing ............................................................................ 7 E. Chemical Properties ............................................................................................................... 9 F. Identification and Analysis ..................................................................................................... 9 3. Ease of [...]
Lire la suiteCannabidiol for Viral Diseases : Hype or Hope ? Alex Mabou Tagne, Barbara Pacchetti, Mikael Sodergren, Marco Cosentino, and Franca Marino Cannabis and Cannabinoid Research, 2020,1-11. Doi : 10.1089/can.2019.0060 Abstract Background : The possibility of cannabidiol (CBD) to be used as an antiviral or to treat viral diseases has received limited attention so far, despite the growing number of claims that CBD could be used for the treatment of viral infection-related conditions. Aim and Methods : Therefore, we systematically retrieved and critically evaluated the scientific literature available on PubMed and the claims on the Internet, to assess the current state of knowledge on the use of [...]
Lire la suiteAnticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent Royston A. Gray, Colin G. Stott, Nicholas A. Jones, Vincenzo Di Marzo, and Benjamin J. Whalley Cannabis and Cannabinoid Research, 2019,1-5. Doi : 10.1089/can.2019.0028 Abstract Introduction : Highly purified cannabidiol (CBD) (approved as Epidiolex in the United States) has demonstrated efficacy with an acceptable safety profile in patients with Lennox–Gastaut or Dravet syndrome in four randomized controlled trials. CBD possesses affinity for many target classes with functional effects relevant to the pathophysiology of many disease types, including epilepsy. Although the mechanism of action of CBD underlying the reduction [...]
Lire la suiteNeuroprotective Effect of Cannabidiol Against Hydrogen Peroxide in Hippocampal Neuron Culture Jungnam Kim, Ji Yu Choi, Jeongyeon Seo, and Insung S. Choi Cannabis and Cannabinoid Research, 2020,Volume X, Number X, Doi : 10.1089/can.2019.0102 Abstract Introduction: Reports on the neurotoxic and neuroprotective effects of cannabidiol (CBD) have not been in complete accord, showing different and somewhat contradictory results depending upon the brain cell types and experimental conditions employed. This work systematically examines the neuroprotective capability of CBD against oxidative stress (i.e., hydrogen peroxide [H2O2]) as well as its toxicity profile in the in vitro culture platform of primary hippocampal neurons. Materials and Methods: The low cell-density (100 neurons [...]
Lire la suiteIs cannabis an effective treatment for anxiety disorders ? https://www.anxiety.org/is-cannabis-an-effective-treatment-for-anxiety-what-research-shows Lindsey Salerno, M.Ed. from Philadelphia College of Osteopathic Medicine Jesse McCann, B.S. from University of Pennsylvania, School of Medicine Shari Lieblich, B.S. from University of Pennsylvania, School of Medicine Jeremy Tyler, Psy.D. from University of Pennsylvania Is cannabis really an effective treatment for anxiety? Research and evidence shows mixed results so learn the facts here and consult a professional. Facts v. Fiction: What the research says What is cannabis (marijuana)? What are common misconceptions? Yes - cannabis can be an effective anxiety treatment - but the opposite is also true Participate in a clinical trial [...]
Lire la suiteUse of Cannabidiol for the Treatment of Anxiety : A Short Synthesis of Pre-Clinical and Clinical Evidence Madison Wright, Patricia Di Ciano, and Bruna Brands Cannabis and Cannabinoid Research, 2019, Volume X, Number X, 1-6. Doi : 10.1089/can.2019.0052 Abstract Anxiety disorders have the highest lifetime prevalence of any mental illness worldwide, leading to high societal costs and economic burden. Current pharmacotherapies for anxiety disorders are associated with adverse effects and low efficacy. Cannabidiol (CBD) is a constituent of the Cannabis plant, which has potential therapeutic properties for various indications. After the recent legalization of cannabis, CBD has drawn increased attention as a potential treatment, as [...]
Lire la suiteDown-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer Valeria Tutino, Maria Gabriella Caruso, Valentina De Nunzio, Dionigi Lorusso, Nicola Veronese, Isabella Gigante, Maria Notarnicola and Gianluigi Giannelli Cancers, 2019, 11, 708, 1-14. doi :10.3390/cancers11050708 Abstract : Changes in the regulation of endocannabinoid production, together with an altered expression of their receptors are hallmarks of cancer, including colorectal cancer (CRC). Although several studies have been conducted to understand the biological role of the CB1 receptor in cancer, little is known about its involvement in the metastatic process of CRC. The aim of this study was to investigate the [...]
Lire la suiteNonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats Michiru Nagao, Yukako Nakano, Masataka Tajima, Erika Sugiyama, Vilasinee Hirunpanich Sato, Makoto Inada, and Hitoshi Sato Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. DOI: 10.1089/can.2019.0098 Abstract Introduction : Cannabidiol (CBD) is known to affect the pharmacokinetics of other drugs through metabolic inhibition of CYP2C19 and CYP3A4. However, there is a lack of in vivo evidence for such drug interactions. Therefore, we investigated the saturability of CBD metabolism and CBD-drug interactions through inhibition of CYP3A in vivo. Materials and Methods : A nanoemulsion formulation of CBD (CBD-NE) was orally administered to [...]
Lire la suiteCannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats Ewa Kozela & Martyna Krawczyk & Tomasz Kos & Ana Juknat & Zvi Vogel & Piotr Popik Molecular Neurobiology, 2019, Doi : 10.1007/s12035-019-01831-2 Abstract Cannabidiol (CBD), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia. The mechanisms of these beneficial effects of CBD are unknown. Here, we examined behavioral effects of CBD in a pharmacological model of schizophrenia-like cognitive deficits induced by repeated ketamine (KET) administration. In parallel, we assessed transcriptional changes behind CBD activities in the prefrontal cortex (PFC), the [...]
Lire la suite